Results 11 to 20 of about 8,055 (251)
Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
CPT: Pharmacometrics & Systems PharmacologyTirzepatide is a first‐in‐class glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist approved as for the treatment of type 2 diabetes mellitus.
Karen Schneck, Shweta Urva
doaj +2 more sources
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Journal of Obesity & Metabolic Syndrome, 2023 The combination of glucagon-like peptide-1 (GLP-1) with other gut hormones including the glucose-dependent insulinotropic polypeptide (GIP) has been explored to complement and enhance further the GLP-1 effects on glycemia and weight loss.
Rachel Sinha +3 more
doaj +5 more sources
Appendicitis After Initiation of Tirzepatide [PDF]
Diabetes, Metabolic Syndrome and ObesityGarrett Chan1, Mariam Ansar1, Marlena Klein1,21Department of Internal Medicine, Cooper University Hospital, Camden, New Jersey, USA; 2Cooper Medical School of Rowan University, Camden, New Jersey, USACorrespondence: Garrett Chan, Email chan-garrett ...
Chan G, Ansar M, Klein M
doaj +1 more source
Tirzepatide Prescribing Practices and Efficacy in Patients with Diabetes and Chronic Kidney Disease at a Large Tertiary Care Center in the United States [PDF]
Diabetes, Metabolic Syndrome and ObesitySriya Amruta Kosaraju,1 Rong M Zhang2 1Department of Biomedical Sciences, University of Missouri-Kansas City, Kansas City, MO, USA; 2Department of Medicine-Division of Endocrinology, Washington University, St Louis, MO, USACorrespondence: Rong M Zhang ...
Kosaraju SA, Zhang RM
doaj +1 more source
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis [PDF]
, 2022 Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. Its association with cardiovascular outcomes requires evaluation. This pre-specified cardiovascular meta-
McGuire, Darren K. +6 more
core +1 more source
Tirzepatide adds hepatoprotection to its armoury
, 2022 In The Lancet Diabetes & Endocrinology, Gastaldelli and colleagues present their findings from the SURPASS-3 MRI, a substudy of the randomised, open-label, parallel-group, phase-3 SURPASS-3 trial (1).
Giovanni Targher, Targher, Giovanni
core +1 more source
, 2022 Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the ...
Yahiya Y. Syed (6594444)
core +1 more source
New Drug: Tirzepatide (Mounjaro™)
, 2023 Type 2 diabetes mellitus (T2DM) is the most common form of diabetes and is a chronic and progressive illness. Millions of Americans have T2DM and many patients do not achieve the recommended blood glucose levels.
Gettman, Lana, Pharm.D.
core +1 more source
Tirzepatide (Mounjaro)-induced acute pancreatitis and ketoacidosis in an adult nondiabetic patient
Saudi Journal for Health SciencesTirzepatide (Mounjaro) is a new medication approved for type 2 diabetes and obesity treatment. It works by activating the receptors for both glucose-dependent insulinotropic peptide and glucagon-like peptide-1.
Asma Ali Sallam +2 more
doaj +1 more source
Tirzepatide to treat diabetes and obesity.
, 2023 reservedQuesto lavoro di tesi propone di fornire una descrizione dettagliata di entrambe le patologie, diabete ed obesità, con relative cure e trattamenti ponendo particolare attenzione al nuovo farmaco tirzepatide.This thesis work aims to provide a ...
MANZATI, SOFIA
core